Article: Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya

Background: Hereditary Tyrosinemia type I (HTI) is a metabolic disease caused by deficiency of fumarylacetoacetate hydrolase enzyme.

Objectives: This study reports beside its clinical and biochemical presentation, the outcome of NTBC [2- (2-nitro-4-trifloro-methylbenzoyl)-1, 3-cyclohexanedion] treatment of the disease and evaluates its biochemical markers in 16 pediatric Libyan patients.

Patients And Methods: The diagnosis was based on presence of high tyrosine levels in blood and succinylacetone in urine.

Results: The consanguinity rate was 81.2%, the median age at onset, at diagnosis and at starting treatment were 4.5, 8, and 9.5 months respectively. At presentation hepatomegaly, jaundice, rickets and high gamma glutamyl transferase (GGT) were observed in 87.5% of patients. All patients had extremely high alpha fetoprotein (AFP) and high alkaline phosphatase (ALP) levels. Fifteen patients were treated with NTBC, normalization of PT (Prothrombine time) was achieved in average in 14 days. The other biochemical parameters of liver function (transaminases, GGT, ALP, bilirubin and albumin) took longer to improve and several months to be normalized. Survival rate with NTBC was 86.6%. Patients who started treatment in a median of 3 months post onset observed a fast drop of AFP in 90.6% of patients (P = 0.003). Abnormal liver function and rickets were the common presentations, GGT was an early cholestatic sensitive test. ALP was constantly high even in asymptomatic patients.

Conclusions: In HT1 a faster dropping of AFP is a marker of good prognosis.

Citing Articles

Clinical Spectrum of Hereditary Tyrosinemia Type 1 in a Cohort of Pakistani Children.

Khan S, Fakih M, Taufiq N, Ahmerin A, Bangash A, Malik M Clin Med Insights Pediatr. 2024; 18:11795565241236176.

PMID: 38456192 PMC: 10919130. DOI: 10.1177/11795565241236176.

Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.

Colemonts-Vroninks H, Neuckermans J, Marcelis L, Claes P, Branson S, Casimir G Genes (Basel). 2020; 12(1).

PMID: 33375092 PMC: 7822164. DOI: 10.3390/genes12010003.

Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.

van Ginkel W, Rodenburg I, Harding C, Hollak C, Heiner-Fokkema M, van Spronsen F Paediatr Drugs. 2019; 21(6):413-426.

PMID: 31667718 PMC: 6885500. DOI: 10.1007/s40272-019-00364-4.

Revisiting hereditary tyrosinemia Type 1-spectrum of radiological findings.

Shaikh S, Qureshi A, Faiq S BJR Case Rep. 2019; 5(2):20180001.

PMID: 31501693 PMC: 6726168. DOI: 10.1259/bjrcr.20180001.

References

1.

Paradis K . Tyrosinemia: the Quebec experience. Clin Invest Med. 1996; 19(5):311-6. View

2.

van Spronsen F, Smit G, Wijburg F, Thomasse Y, Visser G, Heymans H . Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inherit Metab Dis. 1995; 18(2):111-4. DOI: 10.1007/BF00711742. View

3.

Schlune A, Thimm E, Herebian D, Spiekerkoetter U . Single dose NTBC-treatment of hereditary tyrosinemia type I. J Inherit Metab Dis. 2012; 35(5):831-6. DOI: 10.1007/s10545-012-9450-9. View

4.

Schiff M, Broue P, Chabrol B, De Laet C, Habes D, Mention K . Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines. J Inherit Metab Dis. 2011; 35(5):823-9. DOI: 10.1007/s10545-011-9429-y. View

5.

Lindstedt S, Holme E, Lock E, Hjalmarson O, Strandvik B . Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992; 340(8823):813-7. DOI: 10.1016/0140-6736(92)92685-9. View

6.

Santra S, Preece M, Hulton S, McKiernan P . Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008; 31(3):399-402. DOI: 10.1007/s10545-008-0817-x. View

7.

Masurel-Paulet A, Poggi-Bach J, Rolland M, Bernard O, Guffon N, Dobbelaere D . NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008; 31(1):81-7. DOI: 10.1007/s10545-008-0793-1. View

8.

van Spronsen F, Thomasse Y, Smit G, Leonard J, Clayton P, Fidler V . Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994; 20(5):1187-91. View

9.

Ahmad S, Teckman J, Lueder G . Corneal opacities associated with NTBC treatment. Am J Ophthalmol. 2002; 134(2):266-8. DOI: 10.1016/s0002-9394(02)01532-5. View

10.

Thimm E, Richter-Werkle R, Kamp G, Molke B, Herebian D, Klee D . Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis. 2011; 35(2):263-8. DOI: 10.1007/s10545-011-9394-5. View

11.

Russo P, Mitchell G, Tanguay R . Tyrosinemia: a review. Pediatr Dev Pathol. 2001; 4(3):212-21. DOI: 10.1007/s100240010146. View

12.

El-Karaksy H, Rashed M, El-Sayed R, El-Raziky M, El-Koofy N, El-Hawary M . Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?. Eur J Pediatr. 2009; 169(6):689-93. DOI: 10.1007/s00431-009-1090-1. View